Abstract LB016: Deep learning identifies pathobiological features within H&E images associated with genomic alterations and progression on anti-PD(L)1 in HUDSON, an AstraZeneca-sponsored Phase II clinical trial

Introduction Machine learning (ML) models offer the potential to provide rich, quantitative characterizations of the tumor and tumor micro-environment (TME). Here we deployed a machine learning-based approach to the analysis of HE 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr LB016.